Future Directions for NSCLC With PACC Mutations

Panelists discuss how new agents such as amivantamab, sunvozertinib, and zipalertinib are expanding therapeutic possibilities for uncommon EGFR mutations, including PACC subtypes.

Panelists discuss how these data may guide sequencing strategies, combining different targeted modalities to overcome resistance and extend patient benefit.

Panelists discuss how emerging non–tyrosine kinase inhibitor approaches—such as antibody-drug conjugates and bispecific antibodies—could further diversify treatment options in the evolving non–small cell lung cancer (NSCLC)landscape.